Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Dec 10, 2023
TickeronGET DAILY SIGNALS
Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ

Installation Industry Stocks($NBIX, $ACAD, $ALKS, $MDXG, $CYCCP...) Surge with an Average 19.6% Monthly GainšŸ“ˆ

The installation industry, particularly in the residential segment, has seen a remarkable surge in stock performance over the past month. Companies operating in this sector, such as Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT), have all contributed to this impressive performance.

🌐Tickers in Industry - $NBIX, $ACAD, $ALKS, $MDXG, $CYCCP, $VCEL, $VTGN, $MRNA 

Choppy Market Trader, Popular Stocks: Market Neutral Strategy (TA&FA)Ā -Ā Annualized Return + 107%

Theme and Group of Tickers Inside the Theme

The theme in focus here is the installation industry, with a specific emphasis on companies engaged in manufacturing home products and items related to home improvement. The notable tickers within this theme include:

  1. Masco Corp. (MAS): Specializes in building and home improvement products.
  2. Installed Building Products Inc. (FIX): Primarily involved in insulation installer operations.
  3. nVent Electric plc. (NVT): Specializes in electrical connections.

Market Cap

The average market capitalization for companies within the installation theme is approximately $5.6 billion. However, there is significant variation within this group, with market caps ranging from $52.3 million to $13.4 billion. Masco Corp. (MAS) holds the highest valuation at $13.4 billion, while the lowest valued company is KEQU at $52.3 million.

High and Low Price Notable News

In the past month, stocks within the installation theme have experienced substantial price movements. On average, these stocks have seen a remarkable monthly price growth of 19.6%. The average weekly price growth was 6.44%, and the average quarterly price growth was 25.83%.

Notable price movements in this theme include Masco Corp. (MAS) witnessing a significant weekly decline of -5.16% and, in contrast, a weekly gain of +5.43%. nVent Electric (NVT) also saw a notable weekly gain of +5.79%, reflecting the volatility and potential for substantial returns in this sector.

Volume

The trading volumes for stocks in the installation theme have exhibited some interesting trends. On average, there was a weekly volume decrease of -4.76% in the past month, while the monthly and quarterly volume trends showed even more significant declines of -34.01% and -16.5%, respectively.

It's worth noting that nVent Electric's stock witnessed a remarkable daily volume growth of 99% of the 65-Day Volume Moving Average on August 1, 2023. Similarly, Griffon stock experienced a one-day volume surge, reaching a growth of 296% of the 65-Day Volume Moving Average on June 17, 2023.

Fundamental Analysis Ratings

While specific fundamental analysis ratings are not provided in the information given, it's clear that the installation industry, particularly in the residential segment, is exhibiting strong performance. The impressive monthly price growth of 19.6% underscores the sector's potential for investors seeking growth opportunities.

The installation industry, encompassing companies involved in home improvement and related products, has shown outstanding stock performance over the past month. Investors should take note of the opportunities presented by stocks like Masco Corp. (MAS), Installed Building Products Inc. (FIX), and nVent Electric plc. (NVT) in this thriving sector.

NBIXĀ :Ā On November 24, 2023, NBIX exhibited a noteworthy shift in its trajectory as it crossed above its 50-day Moving Average. Historically, such occurrences have often translated into positive momentum, with 32 out of 39 comparable instances resulting in subsequent price increases over the following month. With an 82% probability, the odds appear favorable for NBIX to sustain its upward trajectory. Investors may find this development an encouraging sign for potential gains in the near future.

ACADĀ :Ā ACAD Pharmaceuticals recently exhibited a notable shift in its stock trajectory, breaching its 50-day Moving Average on December 5, 2023. This movement signifies a potential reversal from its previous upward momentum to a bearish trend. Historical analysis reveals that in 35 out of 45 comparable scenarios, ACAD's stock experienced further decline in the subsequent month. This pattern suggests a 78% probability of the stock continuing its downward trend. Investors and market analysts are closely monitoring this development, considering its implications for future investment strategies and market positioning related to ACAD.

ALKSĀ :Ā ALKS Pharmaceuticals exhibited a significant shift in market sentiment as its Momentum Indicator ascended above the zero mark on November 16, 2023. This transition is widely interpreted as a precursor to a new upward trend in the stock's performance. Investors and traders are advised to consider strategies like purchasing shares or opting for call options in anticipation of potential gains. Tickeron's A.I.dvisor analyzed 95 comparable events where the indicator turned positive. In 76 of these instances, ALKS's stock price increased in the subsequent period, indicating an 80% likelihood of a continued upward movement. This trend presents a promising opportunity for market participants focusing on ALKS.

Ā 

Related Ticker: NBIX, ACAD, ALKS, MDXG, BGMSP, VCEL, VTGN, MRNA

NBIX sees MACD Histogram just turned negative

NBIX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 19, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 36 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 68%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NBIX moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 23 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 52%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NBIX as a result. In 46 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 52%.

The 50-day moving average for NBIX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

NBIX moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NBIX crossed bullishly above the 50-day moving average on November 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where NBIX advanced for three days, in 224 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

NBIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 207 of 278 cases where NBIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. NBIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.531) is normal, around the industry mean (6.379). P/E Ratio (23.352) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.280) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (4.587) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a product based biopharmaceutical company

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
6027 Edgewood Bend Court
Phone
+1 858 617-7600
Employees
2000
Web
https://www.neurocrine.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.